Research · Sep 3, 2026
[EHC] Encompass Health Thesis 2026: IRF Cycle Drives De Novo Hospital Pipeline
Encompass Health Corp. (NYSE: EHC) FY2025 revenue ~$5.65-5.85B (+8-12%) with adj. EPS ~$4.85-5.30 reflecting continued post-2024 ~$5.65-5.85B aggregate Inpatient Rehabilitation Facility (IRF) revenue (~100% aggregate revenue mix; selected primary post-January 2023 Enhabit Home Health & Hospice spinoff IRF-focused pure-play; selected ~165+ aggregate IRF hospitals + selected ~10+ aggregate annual de novo IRF hospital openings) under continued President + CEO Mark Tarr since 2017 (~8-year tenure as Encompass Health CEO; selected post-January 2023 Enhabit Home Health & Hospice spinoff). One of the largest US Inpatient Rehabilitation Facility (IRF) hospital operators. Founded 1984 as HealthSouth Corporation in Birmingham Alabama by Richard Scrushy (~41-year heritage); selected post-2018 HealthSouth → Encompass Health rebrand; selected post-1986 NYSE listing; selected post-January 2023 Enhabit spinoff; selected post-2017 Mark Tarr CEO appointment. Headquartered in Birmingham Alabama; ~46,000+ employees globally with ~$5.65-5.85B revenue. One primary business: Inpatient Rehabilitation Facility (~100% ~$5.65-5.85B). Geographic mix: US ~100%; selected primary South + Southeast + Mid-Atlantic + Midwest + Texas + Florida. IRF cycle: ~$5.65-5.85B IRF revenue; ~165+ aggregate IRF hospitals; ~10,000+ aggregate licensed beds; ~225,000-235,000 aggregate annual discharges; ~75-80% aggregate occupancy; ~+5-8% aggregate same-hospital admission growth; ~+5-7% aggregate net revenue per discharge growth. De novo hospital pipeline + post-January 2023 Enhabit spinoff focus: ~10+ aggregate annual de novo IRF hospital openings; ~30+ aggregate JV partner hospitals; ~$280-330M aggregate annual de novo + acquisition CapEx. President + CEO Mark Tarr since 2017 (~8-year tenure); CFO Doug Coltharp. Capital return: ~$0.68 annual dividend FY2025 (~+10-15% growth post-2024 dividend acceleration; ~5-year continuous dividend track post-2020); ~$200-300M aggregate FY2024-2025 buyback program (~$100-150M aggregate FY2025); aggregate capital return ~$170-220M FY2025; net leverage ratio ~3.0-3.5x; non-investment grade Ba2/BB+ credit rating. FY2026 thesis: IRF cycle + De novo hospital pipeline + selected post-January 2023 Enhabit spinoff focus + ~$0.68 annual dividend + ~5-year continuous dividend track + ~$170-250M aggregate annual capital return + selected potential post-2024 dividend acceleration. Risks: Select Medical Holdings + HCA Healthcare + Tenet Healthcare + Universal Health Services competition, CMS IRF reimbursement, Medicare Advantage payer mix shift, IRF compliance threshold.